APOL3 and neoplasm: Moreover, we chose to perform the subcutaneous xenograft models of APOL3-overexpressed HT29 CRC cells, consistent with previous findings, overexpression of APOL3 significantly inhibits tumor volume (Figure S12) and promotes the efficacy of RSL3 (Figure S13); APOL3-overexpressed HT29 of Fe2+ concentration (Figure S14) and percent of MDA (Figure S15) was markedly increased by treatment of RSL3 in vivo.